Mydrane

Lidocaine Hydrochloride, Phenylephrine Hydrochloride, Tropicamide, the active ingredients in Mydrane, are a local anesthetic; alpha‑1 adrenergic agonist; antimuscarinic presented as a sterile solution for intracameral injection use. It provides intra‑operative pupil dilation and anesthesia during cataract and other intraocular surgeries in adult patients.

GNH USA supplies Mydrane as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, surgical centres and ophthalmology clinics worldwide.

Mydrane is employed in ophthalmic procedures to achieve rapid pupil dilation and intra‑ocular anesthesia. - Cataract surgery: provides effective mydriasis and anesthesia of the anterior chamber. - Other intraocular surgeries (e.g., glaucoma, vitrectomy): facilitates adequate pupil dilation and analgesia. - Anterior segment procedures: enables local anesthesia for procedures such as iridotomy or lens implantation.

Mydrane may be associated with ocular and systemic adverse reactions following intracameral administration.

Common Side Effects: - Transient ocular discomfort or burning sensation. - Mild conjunctival hyperemia. - Temporary increase in intraocular pressure. - Mild corneal edema. - Transient blurred vision. - Mild headache.

Serious or Rare Side Effects: - Severe allergic reaction including anaphylaxis. - Persistent mydriasis lasting beyond the postoperative period. - Sustained elevation of intraocular pressure. - Corneal endothelial toxicity. - Endophthalmitis. - Retinal toxicity.

Prior to using Mydrane, clinicians should consider several precautionary measures to ensure patient safety. - Patient assessment: evaluate ocular health and history of glaucoma. - Contraindications: avoid in patients with known hypersensitivity to any component. - Caution in narrow‑angle glaucoma: risk of inadequate pupil dilation. - Monitor intraocular pressure: check IOP after injection. - Use aseptic technique: maintain sterility during preparation and administration. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Mydrane can interact with systemic and ophthalmic agents that affect vascular tone or anesthetic metabolism.

Major Interactions (Avoid): - Systemic alpha‑adrenergic agonists: may cause additive hypertensive response. - Other topical vasoconstrictors (e.g., epinephrine): risk of excessive pupil dilation. - Concurrent use of additional local anesthetics: increased risk of lidocaine toxicity.

Moderate Interactions (Monitor Closely): - Anticholinergic medications: may enhance mydriatic effect. - Beta‑blockers: possible alteration of intraocular pressure response. - Systemic antihypertensives: may blunt phenylephrine‑induced dilation.